No common malignancy is as rapidly and inevitably fatal as pancreatic ductal
adenocarcinoma (PDA). This grim fact has driven substantial research efforts into this …

The cytosine analogues 5‐azacytosine (azacytidine) and 2′‐deoxy‐5‐azacytidine
(decitabine) are the currently most advanced drugs for epigenetic cancer therapies. These …

The methylation of DNA is an epigenetic modification that can play an important role in the
control of gene expression in mammalian cells. The enzyme involved in this process is DNA …

Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …

The inherent or induced resistance of tumors to cytostatic agents is a major clinical problem.
In this review, we summarize the pre-clinical mechanisms of acquired and inherent …

Purpose RRM1 encodes the regulatory subunit of ribonucleotide reductase and is a
molecular target of gemcitabine. Previous studies showed increased RRM1 expression on …

The mechanisms of resistance to the antimetabolite gemcitabine in non-small cell lung
cancer have not been extensively evaluated. In this study, we report the generation of two …

Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …

The preclinical pharmacology of 5-aza-2′-deoxycytidine (decitabine, 5AZA-CdR) is
reviewed. 5AZA-CdR, an analogue of deoxycytidine, is a prodrug that requires metabolic …

Pancreatic cancer is the most lethal of all solid tumors partially because of its
chemoresistance. Although gemcitabine is widely used as a first selected agent for the …